Page last updated: 2024-12-06

freedom

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Freedom: The rights of individuals to act and make decisions without external constraints. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3050747
SCHEMBL ID9844639
MeSH IDM0008828

Synonyms (11)

Synonym
alachlor - trifluralin mixt
trifluralin-alachlor mixt.
67022-32-6
acetamide, 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)-, mixt. with 2,6-dinitro-n,n'-dipropyl-4-(trifluoromethyl)benzenamine
cannon
alachlor plus trifluralin
freedom
alachlor-trifluralin mixt.
SCHEMBL9844639
DTXSID70217229
cvofkrwywcsdma-uhfffaoysa-n

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The aim of this study was to define fatal adverse events and to examine their association with ESS."( One-year sac regression is associated with freedom from fatal adverse events after endovascular aneurysm repair.
Banno, H; Ikeda, S; Kawai, Y; Niimi, K; Sato, T; Sugimoto, M; Tsuruoka, T, 2023
)
0.91
" We defined ESS as an aneurysm diameter decrease of 10 mm or more at 1 year after EVAR, and we defined fatal adverse events as aneurysm-related death, aneurysm sac rupture, open conversion, secondary type Ia endoleak, or secondary type IIIa/b endoleak."( One-year sac regression is associated with freedom from fatal adverse events after endovascular aneurysm repair.
Banno, H; Ikeda, S; Kawai, Y; Niimi, K; Sato, T; Sugimoto, M; Tsuruoka, T, 2023
)
0.91
" Fatal adverse events occurred in 42 patients (7."( One-year sac regression is associated with freedom from fatal adverse events after endovascular aneurysm repair.
Banno, H; Ikeda, S; Kawai, Y; Niimi, K; Sato, T; Sugimoto, M; Tsuruoka, T, 2023
)
0.91
"ESS was associated with a lower rate of life-threatening adverse events after EVAR."( One-year sac regression is associated with freedom from fatal adverse events after endovascular aneurysm repair.
Banno, H; Ikeda, S; Kawai, Y; Niimi, K; Sato, T; Sugimoto, M; Tsuruoka, T, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" At week 16, more patients in the dupilumab groups achieved the co-primary end points: IGA 0/1 [39% (n = 125) once-weekly dosing, 39% (n = 41) every 2 weeks dosing vs."( Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal.
Thomson, J; Wernham, AGH; Williams, HC, 2018
)
0.48
" The most salient consideration when contemplating LA ART was its clinical efficacy; many participants reported wanting to ensure that it worked as well as daily oral ART, including with less frequent dosing (every 8 versus 4 weeks)."( Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
Antela, A; Bredeek, UF; Davis, W; García Del Toro, M; Garcia Gasalla, M; Griffith, S; Hudson, K; Karver, TS; Kerrigan, D; Kumar, P; Mantsios, A; Margolis, D; Murray, M; Rubio García, R; Swindells, S, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,635)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901418 (25.16)18.7374
1990's2100 (37.27)18.2507
2000's906 (16.08)29.6817
2010's764 (13.56)24.3611
2020's447 (7.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials37 (0.59%)5.53%
Reviews323 (5.14%)6.00%
Case Studies186 (2.96%)4.05%
Observational5 (0.08%)0.25%
Other5,733 (91.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]